JP2012143232A5 - - Google Patents

Download PDF

Info

Publication number
JP2012143232A5
JP2012143232A5 JP2012021947A JP2012021947A JP2012143232A5 JP 2012143232 A5 JP2012143232 A5 JP 2012143232A5 JP 2012021947 A JP2012021947 A JP 2012021947A JP 2012021947 A JP2012021947 A JP 2012021947A JP 2012143232 A5 JP2012143232 A5 JP 2012143232A5
Authority
JP
Japan
Prior art keywords
chain variable
variable region
seq
monoclonal antibody
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012021947A
Other languages
English (en)
Japanese (ja)
Other versions
JP5420688B2 (ja
JP2012143232A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2012021947A priority Critical patent/JP5420688B2/ja
Priority claimed from JP2012021947A external-priority patent/JP5420688B2/ja
Publication of JP2012143232A publication Critical patent/JP2012143232A/ja
Publication of JP2012143232A5 publication Critical patent/JP2012143232A5/ja
Application granted granted Critical
Publication of JP5420688B2 publication Critical patent/JP5420688B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012021947A 2005-12-20 2012-02-03 抗ilt7抗体 Active JP5420688B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012021947A JP5420688B2 (ja) 2005-12-20 2012-02-03 抗ilt7抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005366465 2005-12-20
JP2005366465 2005-12-20
JP2012021947A JP5420688B2 (ja) 2005-12-20 2012-02-03 抗ilt7抗体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2007551124A Division JP5020828B2 (ja) 2005-12-20 2006-12-20 抗ilt7抗体

Publications (3)

Publication Number Publication Date
JP2012143232A JP2012143232A (ja) 2012-08-02
JP2012143232A5 true JP2012143232A5 (enExample) 2013-04-25
JP5420688B2 JP5420688B2 (ja) 2014-02-19

Family

ID=38188642

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007551124A Active JP5020828B2 (ja) 2005-12-20 2006-12-20 抗ilt7抗体
JP2012021947A Active JP5420688B2 (ja) 2005-12-20 2012-02-03 抗ilt7抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2007551124A Active JP5020828B2 (ja) 2005-12-20 2006-12-20 抗ilt7抗体

Country Status (29)

Country Link
US (6) US8084585B2 (enExample)
EP (4) EP3441403A1 (enExample)
JP (2) JP5020828B2 (enExample)
KR (3) KR101585532B1 (enExample)
CN (5) CN101379089B (enExample)
AU (1) AU2006328470B2 (enExample)
BR (1) BRPI0620141B1 (enExample)
CA (2) CA2634116C (enExample)
CY (3) CY1114227T1 (enExample)
DK (3) DK2532681T3 (enExample)
ES (3) ES2416716T3 (enExample)
HK (1) HK1218126A1 (enExample)
HR (2) HRP20130494T1 (enExample)
HU (1) HUE039865T2 (enExample)
IL (1) IL192266A (enExample)
LT (1) LT2913343T (enExample)
ME (1) ME02111B (enExample)
MX (1) MX2008007682A (enExample)
NZ (3) NZ569910A (enExample)
PL (3) PL2532681T3 (enExample)
PT (3) PT2532681E (enExample)
RS (2) RS53752B1 (enExample)
RU (2) RU2456298C2 (enExample)
SG (2) SG170749A1 (enExample)
SI (3) SI2532681T1 (enExample)
TR (1) TR201816574T4 (enExample)
UA (1) UA97946C2 (enExample)
WO (1) WO2007072866A1 (enExample)
ZA (1) ZA200805850B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2892724B1 (fr) * 2005-11-02 2008-01-04 Lab Francais Du Fractionnement Anticorps cytotoxiques diriges contre des anticorps inhibiteurs du facteur viii.
WO2011060076A1 (en) * 2009-11-10 2011-05-19 Amgen Inc. Anti-c-mpl antibodies
WO2011063237A2 (en) 2009-11-19 2011-05-26 Oncomed Pharmaceuticals, Inc. Jagged-binding agents and uses thereof
AR080301A1 (es) 2010-02-24 2012-03-28 Immunogen Inc Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
EP3085387A1 (en) 2010-04-26 2016-10-26 Abraxis BioScience, LLC Sparc binding antibodies and uses thereof
PL2694106T3 (pl) 2011-04-01 2018-06-29 Immunogen, Inc. Sposoby zwiększania skuteczności terapii przeciwnowotworowej opartej na receptorze folr1
DK2828292T3 (da) 2012-03-20 2019-01-02 Biogen Ma Inc Jcv-neutraliserende antistoffer
DK2828284T3 (da) 2012-03-20 2019-06-11 Biogen Ma Inc Jcv-neutraliserende antistoffer
WO2014022758A1 (en) * 2012-08-03 2014-02-06 Dana-Farber Cancer Institute, Inc. Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use
KR20150046316A (ko) 2012-08-31 2015-04-29 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
PT3038650T (pt) 2013-08-30 2021-08-25 Immunogen Inc Anticorpos e ensaios para a deteção do recetor de folato 1
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
CN114292331A (zh) * 2013-12-24 2022-04-08 安斯泰来制药株式会社 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EA035374B1 (ru) * 2015-03-18 2020-06-03 Сиэтл Дженетикс, Инк. Антитела против cd48 и их конъюгаты
SMT202100092T1 (it) * 2015-06-29 2021-03-15 Immunogen Inc Anticorpi anti-cd123 e loro coniugati e derivati
JP6880006B2 (ja) 2015-09-17 2021-06-02 イミュノジェン, インコーポレイテッド 抗folr1免疫複合体を含む治療組み合わせ
CN108463248B (zh) 2015-11-12 2022-10-21 西雅图基因公司 聚糖相互作用化合物及使用方法
EP3377079A1 (en) * 2015-11-19 2018-09-26 Abbvie Stemcentrx LLC Novel anti-emr2 antibodies and methods of use
EP3407820A4 (en) 2016-01-26 2019-11-06 Cyberdontics, Inc. Automated dental treatment system
WO2017132486A1 (en) * 2016-01-27 2017-08-03 Siamab Therapeutics, Inc. Compositions and methods for targeting cancer stem cells
KR20250065434A (ko) * 2016-03-01 2025-05-12 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 폴리오바이러스 수용체(pvr)에 특이적인 항체
JP6979976B2 (ja) * 2016-03-10 2021-12-15 ヴィエラ バイオ,インコーポレーテッド Ilt7結合分子及びその使用方法
WO2017176651A1 (en) 2016-04-04 2017-10-12 True North Therapeutics, Inc. Anti-complement factor bb antibodies and uses thereof
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. GLYCAN INTERACTING COMPOUNDS AND METHOD OF USE
CA3073733A1 (en) * 2017-08-30 2019-03-07 Phanes Therapeutics, Inc. Anti-lag-3 antibodies and uses thereof
US11192944B2 (en) 2017-10-11 2021-12-07 Bioverativ Usa Inc. Methods of inducing complement activity
KR102478433B1 (ko) * 2017-11-17 2022-12-15 머크 샤프 앤드 돔 엘엘씨 이뮤노글로불린-유사 전사체 3 (ilt3)에 대해 특이적인 항체 및 그의 용도
AU2018392717A1 (en) * 2017-12-20 2020-07-09 Albert Einstein College Of Medicine Antibodies to Centrin-1, methods of making, and uses thereof
US11655295B2 (en) * 2018-01-18 2023-05-23 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-LAG-3 antibody and use thereof
TW202003576A (zh) * 2018-05-10 2020-01-16 美商艾博視訊有限公司 活化cd40之單株抗體及其用途
MX2020011894A (es) 2018-05-10 2021-03-29 Cyberdontics Usa Inc Taladro dental automatizado.
CN114555637B (zh) * 2019-08-12 2026-01-06 比昂生物制剂公司 针对ilt2的抗体及其用途
EP4041392A1 (en) 2019-10-08 2022-08-17 Nectin Therapeutics Ltd. Antibodies against the poliovirus receptor (pvr) and uses thereof
WO2021113702A1 (en) * 2019-12-06 2021-06-10 Viela Bio, Inc. Methods of treatment using ilt7 binding proteins
PH12022552558A1 (en) 2020-04-20 2024-04-22 Genzyme Corp Humanized anti-complement factor bb antibodies and uses thereof
EP4208122B1 (en) 2020-09-03 2026-02-11 Perceptive Technologies, Inc. System for directing an automated dental drill
AU2022270101A1 (en) 2021-05-04 2023-10-05 Viela Bio, Inc. Methods of treatment of autoimmune disorders using ilt7 binding proteins
JP2025526370A (ja) 2022-07-27 2025-08-13 ビエラ バイオ インコーポレイテッド 免疫グロブリン様転写物7(ilt7)結合タンパク質を含む製剤
CN115819604B (zh) * 2022-09-09 2025-04-15 季华实验室 抗双链dna抗体、核苷酸片段、磁珠及提取外周血游离dna的方法
EP4680344A1 (en) * 2023-03-16 2026-01-21 Inmagene Pte. Ltd. Ilt7-targeting antibodies and uses thereof
WO2024229470A1 (en) 2023-05-04 2024-11-07 Perceptive Technologies, Inc. Robotic dental system and method of preparing for a robotic dental procedure
CN116948032B (zh) * 2023-09-19 2023-12-12 汇智生物技术(苏州)有限公司 人源cd4单克隆抗体及其制备方法和应用
WO2025118871A1 (zh) * 2023-12-05 2025-06-12 苏州普乐康医药科技有限公司 一种抗bdca-2抗体及其制备方法和应用
WO2026002175A1 (zh) * 2024-06-27 2026-01-02 无锡徕特康生物科技有限公司 靶向ilt7和cd89的髓细胞衔接子抗体及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
US6107090A (en) * 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
EP1156823B1 (en) * 1999-02-12 2008-10-29 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
PL356836A1 (en) * 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US6897067B2 (en) * 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
US20040241167A1 (en) * 2001-06-25 2004-12-02 Nicole Suciu-Foca Ilt3 and ilt4-related compositons and methods
AU2002318944A1 (en) 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
PL369953A1 (en) * 2001-10-13 2005-05-02 Asterion Limited Glycosylphosphatidylinositol containing polypeptides
NZ536475A (en) * 2002-05-24 2008-06-30 Schering Corp Neutralizing human anti-igfr antibody
AU2003252328A1 (en) 2002-08-01 2004-02-23 Ginkgo Biomedical Research Institute Co., Ltd. Method of detecting mouse interferon-producing cells
AU2003289716A1 (en) * 2002-09-12 2004-04-30 Incyte Corporation Molecules for diagnostics and therapeutics
EP1664762A4 (en) 2003-09-03 2008-08-13 Us Gov Health & Human Serv METHOD OF IDENTIFYING AND DIAGNOSIS OF, AND VIEWING, SURVIVAL IN LYMPHOMA
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound

Similar Documents

Publication Publication Date Title
JP2018536393A5 (enExample)
JP2014526898A5 (enExample)
NZ716369A (en) Anti-ox40 antibodies and methods of using the same
JP2017114866A5 (enExample)
JP2020536488A5 (enExample)
JP2013538057A5 (enExample)
JP2012501669A5 (enExample)
JP2014516540A5 (enExample)
JP2014524733A5 (enExample)
JP2011527899A5 (enExample)
JP2014534207A5 (enExample)
JP2012501670A5 (enExample)
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
WO2013054331A8 (en) Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
JP2021500916A5 (enExample)
JP2020501532A5 (enExample)
JP2016026303A5 (enExample)
JP2014518883A5 (enExample)
JP2012012402A5 (enExample)
FI3683235T3 (fi) Anti-IL-33-vasta-aineita ja niiden käyttöjä
JP2016516400A5 (enExample)
RU2017107773A (ru) Антитела, специфичные к ммр9
JP2017508475A5 (enExample)
RU2017113732A (ru) Антитело, которое обладает способностью нейтрализовать субстанцию, обладающую активностью, альтернативной функции фактора свертывания viii (fviii)
JP2014511680A5 (enExample)